• Skip to primary navigation
  • Skip to main content
Aegle Biomedical AG

Aegle Biomedical AG

Saving and protecting eyesight from age-related degeneration

  • Home Page
  • About Us

AMD

Nanomedicine – new ways to heal – the future of medicine

20 February 2023 by Aegle Biomedical

Nanomedicine, the idea of using “nanotechnology” in medicine, might sound like something out of a science fiction novel or movie, however the reality is that nanoparticles (nanomaterials smaller then several nanometers) are already being used in a variety of medical and other applications.

Many people still tend to think of nanotechnology as being about tiny machines or robots which can be injected into a patient to “fix” a problem, whereas in reality much of the field deals with creating “nano sized” version of materials or structures which often exhibit different and useful properties when produced at such a tiny size.

Nanomedicine - not tiny little robots :)

The science of nanotechnology is expanding quickly and has the potential to transform how we approach healthcare. It entails the reshaping of matter at the nanoscale, or on the order of a billionth of a meter, in order to produce new substances, machines, and structures. With this technology, new medical cures and treatments that target illnesses at the cellular level can be created. This strategy, known as nanomedicine, has the potential to enhance patients’ health and wellbeing and treat ailments.

Nanomedicine involves new areas of medical and biotechnology research focusing on properties of matter at the atomic and molecular levels.

The use of nanoparticles in medicine is one of the most exciting aspects of nanotechnology. These minuscule particles, which are typically between 1 and 100 nanometers in size, can be made to target particular bodily cells or tissues. For instance, proteins or antibodies that bind to cancer cells can be coated on nanoparticles to deliver medications directly to the tumor while limiting harm to healthy tissue. Moreover, they can be utilized to deliver therapeutic genes or proteins to certain cells, allowing for the treatment of hereditary diseases or the promotion of tissue regeneration.

Nanoparticles can potentially be employed to increase the potency of currently available medications. Drugs can be made more stable and soluble by being enclosed within nanoparticles, which improves their capacity to be delivered to their target cells. Better medicines for illnesses including cancer, HIV, and Alzheimer’s have already been created using this method.

Nanoscience might also be a source of the needed breakthrough in the fight against atherosclerosis, since nanostructures may be used in both preventing and increasing the stability of atherosclerotic lesions.

One area of interest is creating nanomaterials that are not only efficient, but also well tolerated by the human body.

Nanoparticles can be employed for diagnostic purposes in addition to their potential for therapeutic usage. The ability to see nanoparticles inside the body can be achieved, for instance, by coating them with fluorescent dyes or other imaging agents. The non-invasive alternative to conventional imaging techniques can be used to detect cancers or other abnormal tissues using this method.

Other potential applications of nanotechnology in medicine include: nanoadjuvants with immunomodulatory properties used to deliver vaccine antigens; the nano-knife, an almost non-invasive method of destroying cancer cells with high voltage electricity; and carbon nanotubes, which are already a popular way of repairing damaged tissues and might be used to regenerate nerves in the future.

Although the potential of nanomedicine is intriguing, there are still numerous obstacles that must be overcome before these treatments can be made widely available. Assuring the safety of nanoparticles in the body is one of the toughest challenges. Nanoparticles can easily enter cells and tissues where they may cause harm because of their small size. The development of biocompatible, safely excretable nanoparticles is a current area of research.

Another challenge is the development of scalable manufacturing processes for nanoparticles. While researchers have demonstrated the ability to create nanoparticles with precise sizes and shapes, producing these particles on a large scale for clinical use remains a significant challenge. Indeed our manufacturing partner Aegle Technology SL is working closely with leading experts in nanoparticle engineering to help address this challenge.

Nanomedicine today: Vaccination against COVID-19

One of the most publicised and recent applications of nanomedicine has been the development of vaccines based on messenger RNA technology [such as those developed against Covid-19]. Ribonucleic acid or RNA is embedded in nanoparticles that act as carriers named “vectors”. These vectors protect the molecule and transport it to where it is needed. Being chemically engineered, these nanoparticles are more likely to be accepted by cells.

Nanomedicine - COVID-19 RNA vaccine
Covid-19 RNA vaccine, illustration.

Treatments for cancer

Nanomaterials show very high efficiency in destroying cancer cells and are already undergoing clinical trials.

The results are so promising that nanomaterials might become an alternative to traditional cancer therapy, mostly due to the fact that they allow cancer cells to be targeted specifically and enable detailed imaging of tissues, making planning further therapy much easier.

In the following article,  Duxin Sun (Professor of Pharmaceutical Sciences, University of Michigan) describes how researchers are experimenting with new ways to design tiny particle treatments for cancer.

https://theconversation.com/nanoparticles-are-the-future-of-medicine-researchers-are-experimenting-with-new-ways-to-design-tiny-particle-treatments-for-cancer-180009

At Aegle Biomedical we are working with our partners at Vall d’Hebron Research Institute (VHIR) and Catalan Institute of Nanoscience and Nanotechnology (ICN2) to develop and commercialise new medical treatments based on advanced materials engineering, including a promising new treatment against cancer.

Reducing Oxidative Stress

Oxidative stress occurs anytime there exists an imbalance between antioxidants and free radicals within our body, resulting in an abundance of unchecked reactive free radical species (ROS), which can cause irreversible damage to DNA as they oxidize and modify some cellular components and prevent them from performing their original functions. . 

Recent research shows that treatment with nano-sized versions of cerium oxide (“nanoceria”) not only protect from oxidative stress consequence of inflammation but also modulate the immune response towards inflammation resolution.

Nanoceria as a treatment for “oxidative stress”

We can rebuild him/her

In the 1970s TV series “The Six million dollar man” medical scientists used technology to heal and “rebuild” the astronaut Steve Austin, not only saving his life but giving him “superhuman” abilities.

Many science fiction books, films and comics have theorised about the potential of technology to repair, rebuild and even improve on our biology.

Nanomedicine – The sky is the limit

Nanotechnology and nanoparticles have enormous potential to improve the health and well-being of patients and cure illnesses. The field of nanomedicine is rapidly evolving, and new breakthroughs are being made every day. While there are still many challenges that need to be addressed, the future of nanomedicine is exciting, and we can expect to see many new and innovative therapies emerge in the coming years.

The potential applications for nano medicine are limitless and in future we may be able to cure diseases and conditions which today are lethal or greatly reduce the quality of life.

References:

  1. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
  2. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
  3. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
  4. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-664.

Sponsored by Imperial Twing

Imperial Twing, Become the Vice Archmage of the Empire in this fast-paced strategic card and dice game suitable for families, kids from 8 years and adults of any age!
Coming soon to Kickstarter!

This article has been sponsored by Imperial Twing, Become the Vice Archmage of the Empire in this fast-paced strategic card and dice game suitable for families, kids from 8 years and adults of any age!

Coming soon to Kickstarter!

Follow us on Kickstarter: 

https://www.kickstarter.com/projects/imperialgamesgmbh/imperial-twing

Signup for updates and special offers: https://imperialtwing.com/register/

#imperialgames #imperialtwing #kickstarter #twing #fantasy #fun #family #comingsoon

Filed Under: nanomedicine, Age-related Macular Degeneration, AMD, Innovation, nanoceria

A promising treatment for Age-related Macular Degeneration (AMD)

25 October 2022 by Aegle Biomedical

Age-related macular degeneration, also known as AMD, is a leading cause of vision loss in older adults.

AMD occurs when the macula, the light sensitive tissue at the back of the eye that controls sharp, straight-ahead vision, degenerates with age.

Aging and age-related disorders arise from  the cumulative, long-term damage associated with free-radical production along with a simultaneous decline in antioxidant defences. AMD, retinitis pigmentosa and glaucoma are orphan of treatment.

There are two prominent varieties of AMD, “dry” AMD and “wet” AMD.  The most common is dry AMD, representing about 70-80% of cases.

Cerium Oxide

Cerium is a rare earth element that, in its oxide form, has biomedical potential and has been proven to remove oxidative stress in cases of metabolic imbalances.

Researchers at the Vall d’Hebron Barcelona Hospital have developed “luCeria”, an eyedrop formulation containing cerium oxide in nanoparticle form, that has shown potential for treating AMD.

Laboratory trials on animals have shown luCeria to work effectively, stopping and reversing vision loss.

Cerium Oxide Nanoparticles: Potential for Revolutionizing Treatment of Diseases. Nanotechnology Characterization Tools for Environment (2019)

The key factor in the effectiveness of this treatment is the small size (approx. 3nm) of the cerium oxide, which has been shown to pass through the external barriers and reach the interior segment of the eye, and the retina.

Market Analysis

AMD typically affects individuals from age 55 onwards, with an estimated 8% of individuals in the age group (170 million people globally) suffering from some degree of loss or impairment of vision.

The global market for Age-related Macular Degeneration Treatment was valued at USD 7.45 Billion in 2020 and is projected to reach USD 11.98 Billion by 2028 (https://www.verifiedmarketresearch.com/product/macular-degeneration-treatment-market/)

This estimate is likely to be low as the current approaches are invasive, and only work to slow progression of the disease or endeavour to reduce the risk of onset

Additionally, luCeria can be used as a preventative treatment in at-risk individuals (anyone over the age of 55, and certainly those with a known family history), which can greatly reduce the incidence and subsequent impact of the disease.

We expect it will take at most five additional years to complete clinical trials and obtain full approval for luCeria for use in treating AMD  in humans.

We are also investigating other pathways to commercialise luCeria, including release into the veterinary market to treat similar conditions in dogs and cats.

“luCeria” treatment for AMD

luCeria is a ground-breaking innovation in treating a major disease with potential to improve the quality of life for millions of people worldwide.

The “dry” variant of AMD is currently “orphan of treatment” (there are no effective treatments).

Available options for slowing the progress of “wet” form of the disease include injection of drugs into the eye and laser cauterisation of the retina, both of which are high risk and damaging to the eye.

luCeria has been proven to reverse damage to retinal tissue and restore visual acuity in both “wet” and “dry” forms of AMD.

luCeria is a simple to use, non-invasive, safe and effective eye-drop formulation, used once per day in each eye.

As well as halting and partially reversing the damage done by AMD, luCeria can be taken as a preventative treatment to reduce the onset of AMD.

luCeria is a patented invention supported by significant EU research grants and years of research and development.

Filed Under: Age-related Macular Degeneration, AMD, Innovation

Copyright © 2025 ÆGLE BIOMEDICAL AG · Privacy Policy · Powered by Lyæus

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept